Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
Open Access
- 1 October 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (7), 896-897
- https://doi.org/10.1086/342564
Abstract
(See the editorial commentary by Wingard on pages 891–5)Keywords
This publication has 9 references indexed in Scilit:
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- A Prospective and Retrospective Analysis of the Nephrotoxicity and Efficacy of Lipid‐Based Amphotericin B FormulationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Mortality rates in comparative trials of formulations of amphotericin B.Clinical Infectious Diseases, 2001
- ReplyClinical Infectious Diseases, 2001
- Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with LeukemiaLeukemia & Lymphoma, 2001
- A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile NeutropeniaClinical Infectious Diseases, 2000
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Randomized, Double‐Blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and NeutropeniaClinical Infectious Diseases, 1998
- A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsBritish Journal of Haematology, 1997